These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 23092866)

  • 1. Combination therapy for the treatment and prevention of hepatic encephalopathy.
    Mohammad RA; Regal RE; Alaniz C
    Ann Pharmacother; 2012 Nov; 46(11):1559-63. PubMed ID: 23092866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rifaximin for treatment of hepatic encephalopathy.
    Maclayton DO; Eaton-Maxwell A
    Ann Pharmacother; 2009 Jan; 43(1):77-84. PubMed ID: 19092143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
    Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
    Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
    Ahire K; Sonawale A
    J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of hepatic encephalopathy in the hospital.
    Leise MD; Poterucha JJ; Kamath PS; Kim WR
    Mayo Clin Proc; 2014 Feb; 89(2):241-53. PubMed ID: 24411831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.
    Paik YH; Lee KS; Han KH; Song KH; Kim MH; Moon BS; Ahn SH; Lee SJ; Park HJ; Lee DK; Chon CY; Lee SI; Moon YM
    Yonsei Med J; 2005 Jun; 46(3):399-407. PubMed ID: 15988813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Acute Hepatic Encephalopathy: Comparing the Effects of Adding Rifaximin to Lactulose on Patient Outcomes.
    Courson A; Jones GM; Twilla JD
    J Pharm Pract; 2016 Jun; 29(3):212-7. PubMed ID: 25586470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis.
    Huang E; Esrailian E; Spiegel BM
    Aliment Pharmacol Ther; 2007 Oct; 26(8):1147-61. PubMed ID: 17894657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifaximin for the treatment of hepatic encephalopathy.
    Lawrence KR; Klee JA
    Pharmacotherapy; 2008 Aug; 28(8):1019-32. PubMed ID: 18657018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic encephalopathy: pathophysiology and emerging therapies.
    Sundaram V; Shaikh OS
    Med Clin North Am; 2009 Jul; 93(4):819-36, vii. PubMed ID: 19577116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence.
    Hudson M; Schuchmann M
    Eur J Gastroenterol Hepatol; 2019 Apr; 31(4):434-450. PubMed ID: 30444745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
    Irimia R; Trifan A
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on management of patients with overt hepatic encephalopathy.
    Chacko KR; Sigal SH
    Hosp Pract (1995); 2013 Aug; 41(3):48-59. PubMed ID: 23948621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and emerging strategies for treating hepatic encephalopathy.
    Foster KJ; Lin S; Turck CJ
    Crit Care Nurs Clin North Am; 2010 Sep; 22(3):341-50. PubMed ID: 20691385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disaccharides in the treatment of hepatic encephalopathy.
    Sharma P; Sharma BC
    Metab Brain Dis; 2013 Jun; 28(2):313-20. PubMed ID: 23456517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Lactulose Plus Rifaximin Better than Lactulose Alone in the Management of Hepatic Encephalopathy?
    Butt NI; Butt UI; Kakar AATK; Malik T; Siddiqui AM
    J Coll Physicians Surg Pak; 2018 Feb; 28(2):115-117. PubMed ID: 29394969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rifaximin: new therapeutic indication and future directions.
    Rivkin A; Gim S
    Clin Ther; 2011 Jul; 33(7):812-27. PubMed ID: 21741091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Hepatic Encephalopathy: A Primer.
    Jawaro T; Yang A; Dixit D; Bridgeman MB
    Ann Pharmacother; 2016 Jul; 50(7):569-77. PubMed ID: 27126547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
    Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
    Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapy for hepatic encephalopathy.
    Phongsamran PV; Kim JW; Cupo Abbott J; Rosenblatt A
    Drugs; 2010 Jun; 70(9):1131-48. PubMed ID: 20518580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.